BITGF:OTC-Biotage AB (USD)

COMMON STOCK | | OTC

Last Closing Price

USD 22.00

Change

0.00 (0.00)%

Market Cap

USD 0.77B

Volume

200.00

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Biotage AB (publ), a life science company, provides solutions, knowledge, and experience in the areas of organic and analytical chemistry, as well as for industrial applications in the United States, Europe, Japan, China, and internationally. It offers sample preparation solutions; horizon food and environmental products; microwave synthesis solutions; peptide synthesis and purification solutions; flash purification products; work-up products; evaporation and concentration solutions; and metal scavengers, reagents, scavengers, and custom resins. The company sells its products to pharmaceutical and biotechnical companies, contract research and manufacturing organizations, and academic institutions; and commercial, hospital/bio-analytical, and forensic laboratories, as well as laboratories within food and environmental analysis. The company is headquartered in Uppsala, Sweden.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-05 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BTHI Big Time Holdings, Inc

N/A

USD151.65B N/A N/A
SEMHF Siemens Healthineers AG

N/A

USD57.50B 32.24 N/A
WXIBF WuXi Biologics (Cayman) Inc

+0.28 (+2.08%)

USD52.74B 217.58 24.91
YACAF Yancoal Australia Ltd

N/A

USD51.96B 0.20 N/A
HENOF Henkel AG & Co. KGaA

N/A

USD45.59B 29.48 15.78
MQBKY Macquarie Group Limited

+1.97 (+1.59%)

USD45.00B 25.70 9.51
SUVPF Sartorius Aktiengesellschaft

N/A

USD37.26B 120.70 N/A
PETFF PTT Public Company Limited

N/A

USD36.66B 32.14 0.21
SZHIF Shenzhou International Group H..

N/A

USD36.32B 42.19 N/A
SARTF Sartorius Aktiengesellschaft

+36.00 (+7.74%)

USD36.24B 100.87 59.28

ETFs Containing BITGF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification ()
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 37.50% N/A N/A 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 37.50% N/A N/A 65% D
Trailing 12 Months  
Capital Gain 90.48% N/A N/A 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 90.48% N/A N/A 60% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 13.70% N/A N/A 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.70% N/A N/A 54% F
Risk Return Profile  
Volatility (Standard Deviation) 20.93% N/A N/A 77% C+
Risk Adjusted Return 65.45% N/A N/A 89% B+
Market Capitalization 0.77B N/A N/A 66% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
()
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 40.60 N/A N/A 19% F
Price/Book Ratio 12.69 N/A N/A 13% F
Price / Cash Flow Ratio 5.00 N/A N/A 28% F
EV/EBITDA 280.89 N/A N/A 2% F
Management Effectiveness  
Return on Equity 24.47% N/A N/A 92% A-
Return on Invested Capital 21.45% N/A N/A 84% B
Return on Assets 10.60% N/A N/A 95% A
Debt to Equity Ratio 15.58% N/A N/A 61% D-
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.85 N/A N/A 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.